<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920033</url>
  </required_header>
  <id_info>
    <org_study_id>S2019-0154-0001</org_study_id>
    <nct_id>NCT03920033</nct_id>
  </id_info>
  <brief_title>Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy</brief_title>
  <acronym>SHARE</acronym>
  <official_title>Comparison of Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy (SHARE Trial): a Prospective, Randomized Controlled, Open-label, Multi Center, Superiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with a biochemical recurrence after radical prostatectomy for moderate- or high-
      risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose
      radiation therapy group (65 Gy, 26 fractions) and a control group of standard treatment group
      (66 Gy, 33 fractions). The criteria for stratification at randomization include 1) risk
      groups, 2) androgen deprivation therapy, and 3) PSA before salvage radiation therapy, which
      affect biochemical recurrence.

      It is expected that hypofractionated, accelerated high dose radiation therapy will have a
      superiority in terms of biochemical control to conventional radiation therapy, and the
      present study would like to confirm this. In addition, we aimed to evaluate and compare the
      toxicity and quality of life index of two radiation therapy regimens.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical recurrence-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>PSA &gt;0.2 ng/mLfollowed by a repeat measurement &gt;0.2 ng/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicities</measure>
    <time_frame>Adverse effects occured during radiation therapy, and within 3 months after radiation therapy</time_frame>
    <description>Evaulation using CTCAE 4.0 Evaluation using CTCAE 4.0 CTCAE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicities</measure>
    <time_frame>Adverse effects occured after 3 months since end of radiation therapy</time_frame>
    <description>Evaulation using CTCAE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life 1</measure>
    <time_frame>the date of enrollment, up to 1 week after radiation therapy, 6 months, every year until 5 years</time_frame>
    <description>Expanded prostate cancer index composite (EPIC) Questionnaire Korean version EPIC consists of 50 questions in total divided into four domains: bowel (14 questions), urinary (12 questions), sexual (13 questions), and hormonal aspects (13 questions).
Scores of each domain will be separately reported. Response options for each EPIC item form a Likert scale, and multi-item scale scores will be summed and transformed linearly to a 0-to-100 scale.
The higher the score, the higher the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life 2</measure>
    <time_frame>the date of enrollment, up to 1 week after radiation therapy, 6 months, every year until 5 years</time_frame>
    <description>European Organization for Research and Treatment Core Quality of Life Questionnaire (EORTC QLQ-C30) Korean version EORTC QLQ-C30 consists of 30 questions, and total score will be reported. Response options for each EPIC question form a Likert scale, and multi-item scale scores will be summed and transformed linearly to a 0-to-100 scale.
The higher the score, the higher the quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Biochemical Recurrence</condition>
  <condition>Radiation</condition>
  <condition>Hypofractionation</condition>
  <condition>Dose Escalation</condition>
  <condition>Survival</condition>
  <condition>Radiation Toxicity</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Hypofractionated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>65 Gy/ 26 fractions (fraction size 2.5 Gy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>66 Gy/ 33 fractions (fraction size 2 Gy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Salvage radiation therapy</intervention_name>
    <description>Salvage radiation therapy for biochemical recurrence</description>
    <arm_group_label>Hypofractionated</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed intermediate- or high-risk prostate cancer

          -  Biochemical recurrence after radical prostatectomy (Definition: Serial elevation of
             PSA over 0.2 ng/mL and &lt;=1.0 ng/mL)

          -  ECOG performance status 0-1

          -  Appropriate values of blood tests within 6 months after enrollment Absolute neutrophil
             count (ANC) ≥ 1500 cells/mm3 Platelets ≥ 50,000 cells/mm3 Hemoglobin ≥ 8.0 g/dl

          -  Appropriate values of kidney function within 6 months after enrollment Creatinine &lt;
             2.0 ng/dL

          -  Appropriate values of liver function within 6 months after enrollment total bilirubin
             &lt; 1.5 X maximum normal value alanine aminotransferase or aspartate aminotransferase &lt;
             2.5 X maximum normal value

        Exclusion Criteria:

          -  Clinically gross recurrent tumor

          -  Presence of distant metastasis

          -  Presence of pelvic LN metastasis

          -  History of pelvic irradiation

          -  History of cryotherapy or brachytherapy for prostate cancer

          -  Double primary cancer other than skin/thyroid cancer

          -  Combined serious morbidity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Seok Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Seok Kim, M.D., Ph.D.</last_name>
    <phone>82 2 3010 5614</phone>
    <phone_ext>5614</phone_ext>
    <email>ysk@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yeon Joo Kim, M.D.</last_name>
    <phone>82 2 258 9243</phone>
    <phone_ext>9243</phone_ext>
    <email>kamea1004@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Seok Kim, M.D., Ph.D.</last_name>
      <phone>82 2 3010 5614</phone>
      <phone_ext>5614</phone_ext>
      <email>ysk@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Park, M.D., Ph.D.</last_name>
      <phone>82-2-3410-2616</phone>
      <email>wonp68@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young Seok Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

